Advertisement
Letter to the Editor| Volume 86, ISSUE 4, e84-e86, April 2023

Download started.

Ok

Genomic surveillance of SARS-CoV-2 in mainland China after ending the zero-COVID policy, December 2022–January 2023

  • Pengcheng Liu
    Affiliations
    Department of Clinical Laboratory, Children’s Hospital of Fudan University, National Children’s Medical Center, Shanghai 201102, China
    Search for articles by this author
  • Jin Xu
    Correspondence
    Correspondence to: Department of Clinical Laboratory, Children’s Hospital of Fudan University, 399 Wanyuan Rd, Minhang District, Shanghai 201102, China.
    Affiliations
    Department of Clinical Laboratory, Children’s Hospital of Fudan University, National Children’s Medical Center, Shanghai 201102, China
    Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China
    Search for articles by this author
Published:March 01, 2023DOI:https://doi.org/10.1016/j.jinf.2023.02.040
Genomic surveillance of SARS-CoV-2 in mainland China after ending the zero-COVID policy, December 2022–January 2023
Previous ArticlePolybacterial infection in patients with stable bronchiectasis revealed by metagenomic next-generation sequencing
Next ArticleNon-causal association of COVID-19 with systemic lupus erythematosus: Evidence from a bidirectional Mendelian randomization
      After implementing the dynamic zero-COVID policy for nearly three years, China has recently begun to adjust its COVID-19 prevention and control strategies with the attenuated pathogenicity of omicron subvariants and increasing vaccination coverage, notably by announcing the 10 measures on 7 December 2022.

      Xinhua. China Focus: COVID-19 response further optimized with 10 new measures; 2023. Available from: https://english.news.cn/20221207/ca014c043bf24728b8dcbc0198565fdf/c.html [Accessed February 15, 2023].

      A recent publication in this journal by Jingyi Liang et al. showed that the cumulative SARS-CoV-2 infection rate rose rapidly to 70% within three weeks after the ending of zero-COVID policy in Macao, China.
      • Liang J.
      • Liu R.
      • He W.
      • Zeng Z.
      • Wang Y.
      • Wang B.
      • et al.
      Infection rates of 70% of the population observed within 3 weeks after release of COVID-19 restrictions in Macao, China.
      J Infect. 2023; 4453 (00035-X): S0163
      Herein, we report the genomic characteristics and phylodynamic of SARS-CoV-2 complete genome sequences in mainland China after ending zero-COVID policy based on the viral genomic surveillance data deposited in the Global Initiative on Sharing All Influenza Data (GISAID) database.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. Xinhua. China Focus: COVID-19 response further optimized with 10 new measures; 2023. Available from: https://english.news.cn/20221207/ca014c043bf24728b8dcbc0198565fdf/c.html [Accessed February 15, 2023].

        View in Article
        • Liang J.
        • Liu R.
        • He W.
        • Zeng Z.
        • Wang Y.
        • Wang B.
        • et al.
        Infection rates of 70% of the population observed within 3 weeks after release of COVID-19 restrictions in Macao, China.
        J Infect. 2023; 4453 (00035-X): S0163
        View in Article
        • O’Toole A.
        • Scher E.
        • Underwood A.
        • Jackson B.
        • Hill V.
        • McCrone J.T.
        • et al.
        Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool.
        Virus Evol. 2021; 7: veab064
        View in Article

      4. CDC. COVID data tracker: variant proportions; 2023. Available from: https://covid.cdc.gov/covid-data-tracker/#variant-proportions [Accessed February 15, 2023].

        View in Article
        • Chaguza C.
        • Hahn A.M.
        • Petrone M.E.
        • Zhou S.
        • Ferguson D.
        • Breban M.I.
        • et al.
        Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection.
        Cell Rep Med. 2023; 4: 100943
        View in Article
        • Candido D.S.
        • Claro I.M.
        • de Jesus J.G.
        • Souza W.M.
        • Moreira F.R.R.
        • Dellicour S.
        • et al.
        Evolution and epidemic spread of SARS-CoV-2 in Brazil.
        Science. 2020; 369: 1255-1260
        View in Article
        • Duchene S.
        • Featherstone L.
        • Haritopoulou-Sinanidou M.
        • Rambaut A.
        • Lemey P.
        • Baele G.
        Temporal signal and the phylodynamic threshold of SARS-CoV-2.
        Virus Evol. 2020; 6: veaa061
        View in Article

      8. Xinhua. China Focus: China releases measures to optimize COVID-19 response; 2023. Available from: https://english.news.cn/20221111/d4399114a082438eaac32d08a02bf58d/c.html [Accessed February 15, 2023].

        View in Article

      Article info

      Publication history

      Published online: March 01, 2023
      Accepted: February 27, 2023

      Identification

      DOI: https://doi.org/10.1016/j.jinf.2023.02.040

      Copyright

      © 2023 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX